Evidence map›Paper›PMID 31423283›Full record

ArticleOncology letters2019

Imatinib mesylate and nilotinib decrease synthesis of bone matrix

Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, Meinolf Suttorp, Anne Wiedenfeld, Stefan Beissert, Andrea Bauer, Martina Rauner

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Lysann Michaela KroschwaldDepartment of Dermatology, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany.
Josephine Tabea TauerDepartment of Pediatrics, Shriners Hospital for Children, McGill University, Montreal QC H4A 0A9, Canada.
Sonja Ingrid KroschwaldSimon Alberti Group, Max Planck Institute of Molecular Cell Biology and Genetics, D-01307 Dresden, Germany.
Meinolf SuttorpDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany.
Anne WiedenfeldDepartment of Dermatology, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany.
Stefan BeissertDepartment of Dermatology, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany.
Andrea BauerDepartment of Dermatology, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany.
Martina RaunerDepartment of Medicine III and Center for Healthy Aging, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany.
TU Dresden · DEMax Planck Institute of Molecular Cell Biology and Genetics · DEMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs), such as imatinib (IMA) and nilotinib (NIL), are the cornerstone of chronic myeloid leukemia (CML) treatment via the blockade of the oncogenic

Indexed as

bonechronic myeloid leukemiaimatinibnilotinibosteoblastogenesisreceptor activator of nuclear factor κB ligand

Identifiers

PMID31423283
PMCPMC6614669
OpenAlexW2949176444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.